Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!

The adalimumab, infliximab and etanercept biosimilars market is forecasted to achieve exponential growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 40%, as per The Business Research Company’s market report!

Read More On The Adalimumab, Infliximab And Etanercept Biosimilars Market Report 2022 – https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

The Adalimumab, Infliximab And Etanercept Biosimilars Market Size In 2022 And Forecast
The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $3.10 billion in 2021 to $4.76 billion in 2022 at a compound annual growth rate (CAGR) of 53.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The adalimumab, infliximab and etanercept biosimilar market is expected to reach $18.61 billion in 2026 at a CAGR of 40.6%.

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars.

Request for A Sample Of The Global Adalimumab, Infliximab And Etanercept Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Patent Expiry Of Branded Drugs Is Driving The Growth Of The Adalimumab, Infliximab And Etanercept Biosimilars Market
For instance, In United States FDA approved inflectra, developed by Hospira (a Pfizer Inc company) for the treatment of various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, plaque psoriasis, after the patent expiry of branded drug Remicade. Similarly, Amgen’s Enbrel had its patent expired in the EU and with the expiry of the patent, Benepali (a biosimilar of Enmbrel) was approved by the European Commission. Humira’s patent expired and its biosimilars were made available in the market. FDA has recently (July 2020) approved Hulio, the sixth biosimilar of Humira. Therefore, the patent expiry of branded biologic drugs such as Humira, Enbrel and Remicade will drive the biosimilar market.

Competitive Landscape And The Regional Analysis Of The Adalimumab, Infliximab And Etanercept Biosimilars Market
Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd and Glenmark pharmaceuticals.

The Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2022 covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the adalimumab, infliximab and etanercept biosimilars market.

Biosimilar Versions Upon Their Patent’s Expiry – A Key Trend In The Adalimumab, Infliximab And Etanercept Biosimilars Market
The brand versions of biosimilar drugs are of high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biologic drugs almost doubled in recent years.

Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By The Business Research Company
1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo
2) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Others
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Here Are Some Reports Related To The Adalimumab, Infliximab And Etanercept Biosimilars Market –
Biosimilar Interleukins Global Market Report 2022
Biosimilar Monoclonal Antibodies Global Market Report 2022
Psoriatic Arthritis Treatment Global Market Report 2022

Get In Touch With Us – Call us at:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Found This Article Helpful? Share It On: